Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice

Bone

Volumn 50, Issue 2, 2012, Pages 568-575

  Ferron, Mathieu ^a   McKee, Marc D ^b   Levine, Robert L ^a   Ducy, Patricia ^a   Karsenty, Gérard ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Energy expenditure; Glucose; Insulin; Liver steatosis; Osteocalcin

Indexed keywords

GLUCOSE; INSULIN; OSTEOCALCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL COUNT; CELL VOLUME; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENERGY EXPENDITURE; FATTY LIVER; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; MITOCHONDRION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; SKELETAL MUSCLE; WILD TYPE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ENERGY METABOLISM; FATTY LIVER; GLUCOSE; GLUCOSE TOLERANCE TEST; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MOTOR ACTIVITY; OBESITY; OSTEOCALCIN;

EID: 84855866319     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.04.017     Document Type: Article

References (30)

1. Fukumoto S., Martin T.J. Bone as an endocrine organ. Trends Endocrinol Metab 2009, 20(5):230-236.
2. de Paula F.J., Horowitz M.C., Rosen C.J. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 2010, 26(8):622-630.
3. Razzaque M.S. Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism?. Nephrol Dial Transplant 2011, 26(1):42-45.
4. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130(3):456-469.
5. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142(2):296-308.
6. Kanazawa I., Yamaguchi T., Yamauchi M., Yamamoto M., Kurioka S., Yano S., et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011, 22(1):187-194.
7. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94(1):45-49.
8. Yeap B.B., Chubb S.A., Flicker L., McCaul K.A., Ebeling P.R., Beilby J.P., et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010, 163(2):265-272.
9. Yamauchi M., Yamaguchi T., Nawata K., Takaoka S., Sugimoto T. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr 2010, 29(6):761-765.
10. Winhofer Y., Handisurya A., Tura A., Bittighofer C., Klein K., Schneider B., et al. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care 2010, 33(1):139-143.
11. Kim S.H., Lee J.W., Im J.A., Hwang H.J. Serum osteocalcin is related to abdominal obesity in Korean obese and overweight men. Clin Chim Acta 2010, 411(23-24):2054-2057.
12. Diamanti-Kandarakis E., Livadas S., Katsikis I., Piperi C., Aimilia M., Papavassiliou A.G., et al. Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab 2010, 29(2):201-206.
13. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y.C., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 2009, 161(5):723-729.
14. Oury F., Sumara G., Sumara O., Ferron M., Chang H., Smith C.E., et al. Endocrine regulation of male fertility by the skeleton. Cell 2011, 144(5):796-809.
15. Pi M., Wu Y., Quarles L.D. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res 2011, 26(7):1680-1683.
16. Fulzele K., Riddle R.C., DiGirolamo D.J., Cao X., Wan C., Chen D., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142(2):309-319.
17. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008, 105(13):5266-5270.
18. Piters K.M., Kumar D., Pei E., Bessman A.N. Comparison of continuous and intermittent intravenous insulin therapies for diabetic ketoacidosis. Diabetologia 1977, 13(4):317-321.
19. Pertzelan A., Kauli R., Assa S., Greenberg D., Laron Z. Intermittent treatment with human growth hormone (GH) in isolated GH deficiency and in multiple pituitary hormone deficiencies. Clin Endocrinol (Oxf) 1976, 5(1):15-24.
20. Kaji T., Tanaka H., Holst J.J., Redstone H., Wallace L., de Heuval E., et al. The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. Eur J Pharmacol 2008, 596(1-3):138-145.
21. Ferron M., Wei J., Yoshizawa T., Ducy P., Karsenty G. An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem Biophys Res Commun 2010, 397(4):691-696.
22. Turner R.C., Holman R.R., Matthews D., Hockaday T.D., Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979, 28(11):1086-1096.
23. Rossmeisl M., Rim J.S., Koza R.A., Kozak L.P. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003, 52(8):1958-1966.
24. Ricquier D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc 2005, 64(1):47-52.
25. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92(6):829-839.
26. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6):1109-1122.
27. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006, 87(1):1-16.
28. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114(2):147-152.
29. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94(3):827-832.
30. Kindblom J.M., Ohlsson C., Ljunggren O., Karlsson M.K., Tivesten A., Smith U., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009, 24(5):785-791.